Altimmune, Inc. Common Stock (ALT) — Analysis Summary
Altimmune, Inc. Common Stock (ALT) has a market cap of $581.48M with year-over-year revenue growth of +105.0%. Net margin stands at -214861.0%. The stock trades at a P/E ratio of -6.4.
Key Takeaways
- Revenue changed +105.0% year-over-year
- Net margin of -214861.0%
- P/E ratio of -6.4
Compared to other companies in the PHARMACEUTICAL PREPARATIONS sector, ALT posted revenue growth of +105.0% and trades at a P/E of -6.4.
Altimmune, Inc. Common Stock (ALT)
UPDATED — ET · SOURCE POLYGON
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
Interest coverage at -35.9x — earnings do not cover interest payments
Operating margin at -236385.4% — severe operating losses
Net margin at -222148.8% — losses exceed revenue (possible one-time charges)
Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.
Sector
PHARMACEUTICAL PREPARATIONS
Employees
57
Headquarters
GAITHERSBURG, MD
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.